Uterine fibroid

Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment

Retrieved on: 
Tuesday, March 19, 2024
Principal, Spherion, Uterine fibroid, Organization, Growth, Health, Diabetes, Business administration, Patient, Xavier University, Medtronic, Engineering, Senior, McKesson Corporation, Woman, Marketing, Michigan State University, Minnesota State University Moorhead, Market access, Ethicon, Human resources, Management

The addition of these executive team members will support the company’s continued growth and adoption of the innovative Sonata Treatment.

Key Points: 
  • The addition of these executive team members will support the company’s continued growth and adoption of the innovative Sonata Treatment.
  • Commenting on these appointments, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “I am very pleased to welcome Ted Stephens, Keith Chrzanowski, and Laurie Sandberg to Gynesonics.
  • Their collective contributions will help further accelerate adoption of the Sonata Treatment and help deliver on our commitment to provide women with a safe, effective alternative to more invasive treatment options for symptomatic fibroids.”
    Mr. Ted Stephens joins Gynesonics as its Chief Marketing and Strategy Officer.
  • Prior to joining Gynesonics he provided outstanding human resource and operational leadership to achieve success within several industries.

Theromics Inc. Receives National Science Foundation Grant for Innovative Ablation Therapy Technology

Retrieved on: 
Tuesday, March 12, 2024
Principal, Uterine fibroid, Hysterectomy, Thermal, National Science Foundation, Patient, Research, Dartmouth College, Kansas State University, Brown University, NSF, Publication, Phase, FDA

WEST BRIDGEWATER, Mass., March 12, 2024 /PRNewswire/ -- Theromics Inc., a leading developer of products for the interventional oncology and interventional radiology markets, has announced the receipt of a $1M STTR Phase II grant from the National Science Foundation. The funding will support further studies of the company's innovative technology, HeatSYNC™, a nano-polymer gel designed to enhance the effectiveness of ablation therapy of abnormal tissue and allow controlled delivery of drugs directly into soft tissue with reduced side effects.

Key Points: 
  • WEST BRIDGEWATER, Mass., March 12, 2024 /PRNewswire/ -- Theromics Inc ., a leading developer of products for the interventional oncology and interventional radiology markets, has announced the receipt of a $1M STTR Phase II grant from the National Science Foundation.
  • The funding will support further studies of the company's innovative technology, HeatSYNC™, a nano-polymer gel designed to enhance the effectiveness of ablation therapy of abnormal tissue and allow controlled delivery of drugs directly into soft tissue with reduced side effects.
  • Damian Dupuy, MD, co-founder and chief medical officer of Theromics, will oversee ablation procedures at the various institutions.
  • Dr. Dupuy has over two hundred publications in professional journals and is one of the pioneers in image-guided thermal ablation.

Texas Children's Announces Physician Leadership Team at North Austin Campus

Retrieved on: 
Thursday, January 25, 2024
Senior, Child, Woman, Stanford University, Rodale, Inc., Patient, Uterine fibroid, Texas Children's Hospital, Endometriosis, Chiari malformation, Neurology, DRS, Cardiology, Intervention, Gynaecology, Plastic, Hepatology, Baylor College of Medicine, PALS, Pediatrics, Baylor University, Strategic planning, Obstetrics and gynaecology, Medicine, Hospital, Service, Radiology, Rheumatology, Most, Gastroenterology, ERAS, Plastic surgery, American College, Physician, Nursing

"We are honored to bring such amazing talent to our hospital," said Russ Williams , Senior Vice President of Texas Children's North Austin Campus.

Key Points: 
  • "We are honored to bring such amazing talent to our hospital," said Russ Williams , Senior Vice President of Texas Children's North Austin Campus.
  • A past winner of the Most Valuable Physician award at St. David's South Austin Medical Center, she is thrilled to bring her expertise to Texas Children's Hospital North Austin.
  • With these new appointments, Texas Children's Hospital North Austin Campus is ready to expand that tradition of exceptional care for children and women in Austin."
  • Located at 9835 North Lake Creek Parkway, Texas Children's North Austin will connect patients and families to Texas Children's numerous subspecialties including cardiology, oncology, neurology, pulmonology, gastroenterology, rheumatology, fetal care and more.

Runway Growth Finance Corp. Provides Fourth Quarter 2023 Portfolio Update

Retrieved on: 
Thursday, January 11, 2024
Stroke, Uterine fibroid, Credit, Growth, GPS, Investment, Communication, Synack, Bombora, Snag (website), Partial, Completion, Health, Security (finance)

“Runway Growth generated strong momentum during the fourth quarter, capitalizing on investment opportunities as green shoots emerged in the origination environment,” said Greg Greifeld, Acting Chief Executive Officer of Runway Growth, and Deputy Chief Investment Officer and Head of Credit of Runway Growth Capital LLC.

Key Points: 
  • “Runway Growth generated strong momentum during the fourth quarter, capitalizing on investment opportunities as green shoots emerged in the origination environment,” said Greg Greifeld, Acting Chief Executive Officer of Runway Growth, and Deputy Chief Investment Officer and Head of Credit of Runway Growth Capital LLC.
  • Runway Growth’s creative financing solutions and strategic growth capital will fill a void for borrowers seeking non-dilutive alternatives to a challenging fundraising environment.”
    In the fourth quarter of 2023, Runway Growth funded eight investments: three investments in new portfolio companies and five investments in existing portfolio companies.
  • During the fourth quarter ended December 31, 2023, Runway Growth experienced two prepayments totaling $61.7 million and scheduled principal amortization of $0.3 million.
  • As of December 31, 2023, the Runway Growth portfolio included 31 debt investments to 29 portfolio companies and 76 equity investments in 48 portfolio companies, including 25 portfolio companies where Runway Growth holds both a debt and equity investment.

Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women

Retrieved on: 
Thursday, January 11, 2024
Oncology, Health, Consumer, Women, Surgery, Health Technology, General Health, Hologic, AUB, Woman, Patient, Uterine fibroid, MD, Pelvic pain, Life, Multimedia, Fibroid, HOLX, Pain, Better, Bleeding, Hysterectomy, Fatigue, Marketing, Physician, Birth control

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.
  • Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase awareness about daily quality-of-life challenges such as heavy and disruptive periods, pelvic pain and fibroids, while also educating women about available treatment options.
  • The campaign hub, BetterIsPossible.com , offers downloadable materials such as a period symptom quiz, discussion guides and information about potential treatment options.
  • For more information about how Hologic is supporting physicians to discuss hysterectomy-alternative treatment options, visit gynsurgicalsolutions.com/hcp/for-medical-professionals/
    For more information about the Better is Possible campaign and to access educational resources, visit BetterIsPossible.com .

Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids

Retrieved on: 
Tuesday, January 2, 2024
Category 1, Constipation, Commercial, Hysterectomy, Woman, Uterine fibroid, Language, Place of birth, Literature, ACOG, Sonata, American Medical Association, Medicare, Obstetrics, Fibroid, American College, Uterus, Current Procedural Terminology, CPT, Patient, Pressure

The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.

Key Points: 
  • The new code is effective January 1, 2024, and is defined as CPT 58580 Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency.
  • Commenting on the new CPT code, Skip Baldino, President and Chief Executive Officer of Gynesonics said, “We are very pleased that the AMA has established a new Category I code that applies to our Sonata® Procedure for the treatment of uterine fibroids.
  • The code is a critical milestone for the broader adoption of the technology to treat uterine fibroids in the United States.
  • Fibroids are treated from inside the uterus, so the Sonata Procedure requires no incisions, no tissue is surgically removed, and the uterus is preserved.

North Star Vascular & Interventional Opens New Center in Minneapolis

Retrieved on: 
Wednesday, December 20, 2023
Technology, FDA, Health, Robotics, Other Health, Radiology, Surgery, Oncology, Practice Management, Medical Devices, Managed Care, General Health, Hospitals, Health Technology, Patient, Google Images, Varicocele, Artery, Pain management, Peripheral artery disease, Risk, Advocate Christ Medical Center, Knee, Physician, Uterine fibroid, Vascular disease, Intervention, Male, Infertility, Kidney disease, Chronic pain, Thyroid disease, Osteoarthritis, MBA, MD, Vein, Cancer, GE HealthCare, University, Moyamoya disease, Neoplasm, Rush University Medical Center, Fibroid, Interventional radiology, Liver cancer, Hospital-acquired infection, Pelvic congestion syndrome, Radiation, Y-90, Medical imaging

The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.

Key Points: 
  • The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.
  • North Star Vascular & Interventional (NSVI) offers minimally invasive procedures to treat health conditions such as peripheral artery and venous disease, cancer, enlarged prostate, uterine fibroids and more.
  • Jafar Golzarian, MD, FSIR, professor emeritus of interventional radiology at the University of Minnesota Medical School, has authored more than 400 academic articles and national and international lectures on interventional radiology.
  • Bulent Arslan, MD, FSIR is a Professor of Radiology and Chief of Interventional Radiology at the Rush University Medical Center in Chicago.

Robotic Surgery Pioneer Virtuoso Surgical Awarded $1.8 Million in SBIR Funding

Retrieved on: 
Tuesday, November 14, 2023
Technology, Radiology, Health Technology, Oncology, Other Science, Research, Medical Devices, Hospitals, Clinical Trials, Biotechnology, Health, Robotics, Women, Seniors, Managed Care, Men, Nanotechnology, Science, Consumer, Medical Supplies, FDA, Hardware, Surgery, Sale, Otorhinolaryngology, Virtuoso, Cadaver, Gynaecology, Lead (engineering), Entrepreneurship, VISE, Surgeon, Elective surgery, Bladder cancer, SBIR, FACS, ENT, NIH, Neurosurgery, Cancer, BPH, Endoscopy, Small Business Innovation Research, Doctor of Philosophy, Uterine fibroid, Medical device, MD, Engineering

Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.

Key Points: 
  • Medical device company Virtuoso Surgical, Inc. has been awarded a $1.8 million Small Business Innovation Research (SBIR) NIH grant to be received over the next two years.
  • Virtuoso’s robotic surgery system enables a new scale of robotic tools and maneuvers in endoscopic surgery that are not possible using today’s instruments.
  • “We are honored to receive this SBIR Phase II grant as we move toward commercialization of our groundbreaking robotic surgical system ,” said S. Duke Herrell, III, MD, FACS , CEO, Co-Founder and Chief Medical Officer of Virtuoso Surgical.
  • They developed the Virtuoso Surgical system with a design team helmed by COO, Co-founder and Lead Engineer Richard Hendrick, PhD.

Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses

Retrieved on: 
Thursday, November 30, 2023
GPX, Aneurysm, Embolism, Research and development, Risk, Fistula, Tissue, Patient, Refrigeration, Medicine, Internal bleeding, Interventional radiology, ULTRA, Neoplasm, Blood, IDE, Birth, Heel, Investigational device exemption, Investigator's brochure, Uterine fibroid, Medical device, Medical imaging

SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster. 

Key Points: 
  • SALT LAKE CITY, Nov. 30, 2023 /PRNewswire/ -- Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
  • "Embolic particles are hard to visualize during delivery, increasing the risk of off-target embolization and leading to unintended harm of nearby tissues."
  • "ULTRA is visible under x-ray giving clinicians greater control and visualization of the embolic to ensure safe, accurate delivery."
  • The success of the ULTRA embolic platform follows on the heels of another large milestone for Fluidx Medical, as their flagship product the GPX Embolic Device is currently under Investigational Device Exemption (IDE) review with the FDA.

L'ORÉAL USA ANNOUNCES 2023 FOR WOMEN IN SCIENCE AWARDEES, MARKING 20-YEAR COMMITMENT TO WOMEN IN STEM

Retrieved on: 
Monday, November 13, 2023
Woman, Biomedical engineering, Engineering, Gladstone Institutes, NASEM, Infection, Uterus, Johns Hopkins University, Uterine fibroid, Fibrosis, Fertility, Gene editing, Data science, Diplomacy, Health, National academy, Neuroscience, Ageing, California Institute of Technology, Communication, Brain cell, Female, Spina bifida, AAAS, Medicine, Physics, Khwarizmi International Award, DSM-IV codes, Mentorship, Equity, Animal, University, Bangladesh Technical Education Board, University of North Carolina, Cell, UNESCO, Brain, Research, Microbiology, Biotechnology, Fungus, Fellow, CBS, Human, Survival, Neoplasm, Biology, Pharmaceutical industry, Management, STEM, Science

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Today, L'Oréal USA announced the recipients of its 2023 For Women in Science (FWIS) Fellowship program, which grants awards annually to five female postdoctoral scientists to support their research endeavors. This year marks L'Oréal USA's 20th anniversary of helping to advance women in STEM fields through its FWIS program, which has provided more than $5 million in grants to support the work of innovative women scientists.

Key Points: 
  • "L'Oréal USA is proud to recognize this 20th Anniversary milestone of the For Women in Science program.
  • The L'Oréal USA FWIS philanthropic program embodies L'Oréal's fundamental belief in the indispensable connection between science and women.
  • The L'Oréal USA program includes a requirement to ensure recipients are committed to serving as role models for younger generations.
  • For more information about the L'Oréal USA 2023 For Women in Science Fellows or to apply for the L'Oréal For Women in Science 2024 program, please visit: loreal.com/en/usa/pages/group/fwis/ .